Samuel J. Gesten - 12 Aug 2021 Form 4 Insider Report for STAAR SURGICAL CO (STAA)

Role
Chief Legal Officer
Signature
Samuel J. Gesten
Issuer symbol
STAA
Transactions as of
12 Aug 2021
Net transactions value
-$3,150,958
Form type
4
Filing time
13 Aug 2021, 16:22:24 UTC
Next filing
05 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STAA Common Stock Options Exercise $107,672 +6,667 +16% $16.15 49,250 12 Aug 2021 Direct
transaction STAA Common Stock Options Exercise $133,951 +4,495 +9.1% $29.80 53,746 12 Aug 2021 Direct
transaction STAA Common Stock Options Exercise $408,877 +11,364 +21% $35.98 65,110 12 Aug 2021 Direct
transaction STAA Common Stock Options Exercise $197,005 +7,156 +11% $27.53 72,266 12 Aug 2021 Direct
transaction STAA Common Stock Sale $3,998,462 -29,682 -41% $134.71 42,583 12 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STAA Common Stock Options Options Exercise $0 -6,667 -100% $0.000000* 0 12 Aug 2021 Common Stock 6,667 $16.15 Direct
transaction STAA Common Stock Options Options Exercise $0 -4,495 -100% $0.000000* 0 12 Aug 2021 Common Stock 4,495 $29.80 Direct
transaction STAA Common Stock Options Options Exercise $0 -11,364 -67% $0.000000 5,682 12 Aug 2021 Common Stock 11,364 $35.98 Direct F2
transaction STAA Common Stock Options Options Exercise $0 -7,156 -44% $0.000000 8,946 12 Aug 2021 Common Stock 7,156 $27.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.58 to $137.35 inclusive.
F2 The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/14/2022.
F3 The options granted become exercisable as follows: 1/3 on 3/20/2021 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/20/2023.

Remarks:

This Form 4 reflects a sale by Mr. Gesten of Common Stock of the Company pursuant to instructions contained in a pre-established Rule 10b5-1 plan.